3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Trastuzumab
243
Paclitaxel
193
Cyclophosphamide
158
Docetaxel
134
Letrozole
113
Capecitabine
113
Fulvestrant
106
Doxorubicin
103
Bevacizumab
87
Carboplatin
81
exemestane
80
Anastrozole
79
Lapatinib
70
Tamoxifen
69
Albumin-Bound Paclitaxel
57
palbociclib
54
pertuzumab
53
Taxes
51
Gemcitabine
50
Radiotherapy
46
eribulin
43
pembrolizumab
41
Everolimus
41
Ado-Trastuzumab Emtansine
41
Vinorelbine
38
130-nm albumin-bound paclitaxel
35
ixabepilone
32
Epirubicin
28
pegfilgrastim
25
liposomal doxorubicin
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Breast Neoplasms
×
Induction Chemotherapy
×
Clear all
NCT01491737
2020-10-28
PERTAIN
Hoffmann-La Roche
Phase 2
Completed
258 enrolled
18 charts